Since cachexia preferentially causes loss of LBM more than FM, there is a need for a biomarker for the early diagnosis of cachexia, especially the atrophy in skeletal muscle.6, 14 Despite several well-designed interventional clinical trials, cachexia cannot be reversed by conventional nutritional support, appetite stimulant, and recombinant growth hormone.19 Specifically, the loss of muscle mass is recognized as an independent predictor of mortality and a major contributor to functional impairment. The gene discussed is GH1; the disease is Cachexia.